Veradermics Stock
Veradermics, Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Reid Waldman
- Employees
- 37
- Market cap
- $4.5 B
- IPO
- 04/02/2026
Veradermics, Incorporated is a biopharmaceutical enterprise based in New Haven, US, operating within the Healthcare sector and the Biotechnology industry. Founded in 2019, the company focuses on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The development pipeline includes…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Veradermics stock: price history
1D
-5.4%
1W
-16.9%
1M
+6.2%
6M
+42.6%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~39% weaker price swings than usual
Veradermics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Veradermics
Analyst assessment of Veradermics
PRICE TARGET LOW
US$136.00
CONSENSUS
US$162.67
MEDIAN
US$170.00
PRICE TARGET HIGH
US$182.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 16/07/2026
Veradermics stock metrics
P/E
-50.85
P/B
5.41
EV/EBITDA
-43.47
RETURN ON EQUITY
-2.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
–
FLOAT SHARES
35,082,327
AVG. DAILY VOLUME (30D)
853,859
Insider transactions (SEC)
Hollander David
MONTANOVA CAPITAL, LLC
MONTANOVA CAPITAL, LLC
MONTANOVA CAPITAL, LLC
MONTANOVA CAPITAL, LLC
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.4%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Veradermics stock
What does Veradermics do?
Veradermics, Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Reid Waldman, the company employs around 37 people.
The IPO was on 04/02/2026; the stock trades on NYSE under the ticker MANE.
What do analysts say about Veradermics stock?
4 analysts rate the stock, the consensus is Buy (as of 16/07/2026).
The average price target is US$162.67, ranging from US$136.00 to US$182.00, with a median of US$170.00.
This is an external assessment, not a statement by Market Jury.
When does Veradermics report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly -39% stronger than usual.
Does Veradermics pay a dividend?
No, Veradermics currently does not pay a dividend.
Which stocks are comparable to Veradermics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Veradermics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Veradermics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.